Univariate analysis of outcomes based on the type of graft
| Outcomes . | Fresh (N = 2499) . | Cryopreserved (N = 1543) . | P value . | ||
|---|---|---|---|---|---|
| N . | Prob (95% CI) . | N . | Prob (95% CI) . | ||
| Neutrophil recovery (BM only) | 659 | 180 | .598 | ||
| 14 d | 25.9 (22.7-29.4)% | 23.9 (17.9-30.4)% | |||
| 30 d | 95.3 (93.5-96.8)% | 95 (91.3-97.7)% | |||
| Neutrophil recovery (PB only) | 1821 | 1351 | < .001 | ||
| 14 d | 46.2 (43.9-48.5)% | 34.6 (32.1-37.2)% | < .001 | ||
| 30 d | 97.3 (96.5-98)% | 95.5 (94.3-96.5)% | .009 | ||
| Neutrophil recovery (all patients) | 2480 | 1531 | < .001 | ||
| 14 d | 40.8 (38.9-42.7)% | 33.4 (31-35.8)% | < .001 | ||
| 30 d | 96.7 (96-97.4)% | 95.4 (94.3-96.4)% | .041 | ||
| Platelet recovery (BM only) | 640 | 173 | .217 | ||
| 14 d | 5.9 (4.2-7.9)% | 6.4 (3.2-10.5)% | |||
| 30 d | 65 (61.3-68.7)% | 61.8 (54.5-69)% | |||
| 60 d | 92.5 (90.3-94.4)% | 86.7 (81.2-91.4)% | |||
| 100 d | 94.5 (92.6-96.2)% | 92.5 (88-96)% | |||
| Platelet recovery (PB only) | 1802 | 1329 | < .001 | ||
| 14 d | 20.2 (18.4-22.1)% | 13.2 (11.4-15)% | < .001 | ||
| 30 d | 82.8 (81-84.5)% | 73.1 (70.7-75.5)% | < .001 | ||
| 60 d | 93.1 (91.9-94.3)% | 91.1 (89.5-92.6)% | .041 | ||
| 100 d | 94.9 (93.9-95.9)% | 92.8 (91.4-94.1)% | .016 | ||
| Platelet recovery (all patients) | 2442 | 1502 | < .001 | ||
| 14 d | 16.5 (15-18)% | 12.4 (10.8-14.1)% | < .001 | ||
| 30 d | 78.1 (76.5-79.7)% | 71.8 (69.5-74.1)% | < .001 | ||
| 60 d | 93 (91.9-93.9)% | 90.6 (89.1-92)% | .010 | ||
| 100 d | 94.8 (93.9-95.7)% | 92.8 (91.4-94)% | .011 | ||
| aGVHD II-IV | 2313 | 1424 | .115 | ||
| 14 d | 1.1 (0.7-1.5)% | 1.6 (1-2.3)% | |||
| 30 d | 12.8 (11.4-14.1)% | 15.5 (13.7-17.4)% | |||
| 60 d | 28.1 (26.2-29.9)% | 32 (29.6-34.5)% | |||
| 100 d | 32.7 (30.8-34.6)% | 36 (33.5-38.5)% | .042 | ||
| aGVHD III-IV | 2288 | 1413 | .233 | ||
| 14 d | 0.3 (0.1-0.6)% | 0.8 (0.4-1.3)% | |||
| 30 d | 4.6 (3.8-5.5)% | 4.8 (3.8-6)% | |||
| 60 d | 9 (7.9-10.2)% | 8.7 (7.3-10.2)% | |||
| 100 d | 10.4 (9.2-11.7)% | 9.8 (8.3-11.4)% | .504 | ||
| cGVHD (moderate/severe) | 2461 | 1509 | .025 | ||
| 180 d | 9.6 (8.4-10.8)% | 7.9 (6.6-9.4)% | .082 | ||
| 365 d | 19.8 (18.2-21.4)% | 16.9 (15-18.9)% | .023 | ||
| Relapse∗ | 2162 | 1298 | .004 | ||
| 100 d | 7.6 (6.5-8.7)% | 8.1 (6.7-9.6)% | .591 | ||
| 180 d | 13.7 (12.3-15.2)% | 15.3 (13.4-17.3)% | .217 | ||
| 365 d | 19.2 (17.6-20.9)% | 22.2 (19.9-24.5)% | .042 | ||
| NRM∗ | 2162 | 1298 | .068 | ||
| 100 d | 5.5 (4.5-6.5)% | 7.9 (6.5-9.4)% | |||
| 180 d | 9.6 (8.4-10.9)% | 10.6 (9-12.4)% | |||
| 365 d | 13.9 (12.4-15.4)% | 14.7 (12.8-16.7)% | |||
| DFS∗ | 2162 | 1298 | < .001 | ||
| 100 d | 87 (85.5-88.3)% | 84 (82-86)% | .020 | ||
| 180 d | 76.6 (74.8-78.4)% | 74.1 (71.7-76.4)% | .093 | ||
| 365 d | 66.9 (64.9-68.9)% | 63.2 (60.5-65.8)% | .027 | ||
| OS | 2499 | 1543 | .064 | ||
| 100 d | 93.3 (92.3-94.2)% | 91.3 (89.8-92.7)% | |||
| 180 d | 86.8 (85.4-88.1)% | 84.6 (82.7-86.4)% | |||
| 365 d | 76.9 (75.2-78.6)% | 74.6 (72.3-76.8)% | |||
| GRFS | 2220 | 1247 | .287 | ||
| 100 d | 79.4 (77.7-81.1)% | 76.4 (74-78.7)% | |||
| 180 d | 65.5 (63.5-67.5)% | 62.8 (60-65.4)% | |||
| 365 d | 51.1 (49-53.2)% | 50 (47.2-52.8)% | .518 | ||
| Outcomes . | Fresh (N = 2499) . | Cryopreserved (N = 1543) . | P value . | ||
|---|---|---|---|---|---|
| N . | Prob (95% CI) . | N . | Prob (95% CI) . | ||
| Neutrophil recovery (BM only) | 659 | 180 | .598 | ||
| 14 d | 25.9 (22.7-29.4)% | 23.9 (17.9-30.4)% | |||
| 30 d | 95.3 (93.5-96.8)% | 95 (91.3-97.7)% | |||
| Neutrophil recovery (PB only) | 1821 | 1351 | < .001 | ||
| 14 d | 46.2 (43.9-48.5)% | 34.6 (32.1-37.2)% | < .001 | ||
| 30 d | 97.3 (96.5-98)% | 95.5 (94.3-96.5)% | .009 | ||
| Neutrophil recovery (all patients) | 2480 | 1531 | < .001 | ||
| 14 d | 40.8 (38.9-42.7)% | 33.4 (31-35.8)% | < .001 | ||
| 30 d | 96.7 (96-97.4)% | 95.4 (94.3-96.4)% | .041 | ||
| Platelet recovery (BM only) | 640 | 173 | .217 | ||
| 14 d | 5.9 (4.2-7.9)% | 6.4 (3.2-10.5)% | |||
| 30 d | 65 (61.3-68.7)% | 61.8 (54.5-69)% | |||
| 60 d | 92.5 (90.3-94.4)% | 86.7 (81.2-91.4)% | |||
| 100 d | 94.5 (92.6-96.2)% | 92.5 (88-96)% | |||
| Platelet recovery (PB only) | 1802 | 1329 | < .001 | ||
| 14 d | 20.2 (18.4-22.1)% | 13.2 (11.4-15)% | < .001 | ||
| 30 d | 82.8 (81-84.5)% | 73.1 (70.7-75.5)% | < .001 | ||
| 60 d | 93.1 (91.9-94.3)% | 91.1 (89.5-92.6)% | .041 | ||
| 100 d | 94.9 (93.9-95.9)% | 92.8 (91.4-94.1)% | .016 | ||
| Platelet recovery (all patients) | 2442 | 1502 | < .001 | ||
| 14 d | 16.5 (15-18)% | 12.4 (10.8-14.1)% | < .001 | ||
| 30 d | 78.1 (76.5-79.7)% | 71.8 (69.5-74.1)% | < .001 | ||
| 60 d | 93 (91.9-93.9)% | 90.6 (89.1-92)% | .010 | ||
| 100 d | 94.8 (93.9-95.7)% | 92.8 (91.4-94)% | .011 | ||
| aGVHD II-IV | 2313 | 1424 | .115 | ||
| 14 d | 1.1 (0.7-1.5)% | 1.6 (1-2.3)% | |||
| 30 d | 12.8 (11.4-14.1)% | 15.5 (13.7-17.4)% | |||
| 60 d | 28.1 (26.2-29.9)% | 32 (29.6-34.5)% | |||
| 100 d | 32.7 (30.8-34.6)% | 36 (33.5-38.5)% | .042 | ||
| aGVHD III-IV | 2288 | 1413 | .233 | ||
| 14 d | 0.3 (0.1-0.6)% | 0.8 (0.4-1.3)% | |||
| 30 d | 4.6 (3.8-5.5)% | 4.8 (3.8-6)% | |||
| 60 d | 9 (7.9-10.2)% | 8.7 (7.3-10.2)% | |||
| 100 d | 10.4 (9.2-11.7)% | 9.8 (8.3-11.4)% | .504 | ||
| cGVHD (moderate/severe) | 2461 | 1509 | .025 | ||
| 180 d | 9.6 (8.4-10.8)% | 7.9 (6.6-9.4)% | .082 | ||
| 365 d | 19.8 (18.2-21.4)% | 16.9 (15-18.9)% | .023 | ||
| Relapse∗ | 2162 | 1298 | .004 | ||
| 100 d | 7.6 (6.5-8.7)% | 8.1 (6.7-9.6)% | .591 | ||
| 180 d | 13.7 (12.3-15.2)% | 15.3 (13.4-17.3)% | .217 | ||
| 365 d | 19.2 (17.6-20.9)% | 22.2 (19.9-24.5)% | .042 | ||
| NRM∗ | 2162 | 1298 | .068 | ||
| 100 d | 5.5 (4.5-6.5)% | 7.9 (6.5-9.4)% | |||
| 180 d | 9.6 (8.4-10.9)% | 10.6 (9-12.4)% | |||
| 365 d | 13.9 (12.4-15.4)% | 14.7 (12.8-16.7)% | |||
| DFS∗ | 2162 | 1298 | < .001 | ||
| 100 d | 87 (85.5-88.3)% | 84 (82-86)% | .020 | ||
| 180 d | 76.6 (74.8-78.4)% | 74.1 (71.7-76.4)% | .093 | ||
| 365 d | 66.9 (64.9-68.9)% | 63.2 (60.5-65.8)% | .027 | ||
| OS | 2499 | 1543 | .064 | ||
| 100 d | 93.3 (92.3-94.2)% | 91.3 (89.8-92.7)% | |||
| 180 d | 86.8 (85.4-88.1)% | 84.6 (82.7-86.4)% | |||
| 365 d | 76.9 (75.2-78.6)% | 74.6 (72.3-76.8)% | |||
| GRFS | 2220 | 1247 | .287 | ||
| 100 d | 79.4 (77.7-81.1)% | 76.4 (74-78.7)% | |||
| 180 d | 65.5 (63.5-67.5)% | 62.8 (60-65.4)% | |||
| 365 d | 51.1 (49-53.2)% | 50 (47.2-52.8)% | .518 | ||
Clinical evidence of relapse only.